Glaukos Wins FDA Approval for Epioxa Keratoconus Therapy
Reuters
Oct 20, 2025
Glaukos Wins FDA Approval for Epioxa Keratoconus Therapy
Glaukos Corporation has announced that the U.S. Food and Drug Administration (FDA) has approved its Epioxa™ HD / Epioxa™ (Epioxa) New Drug Application for the treatment of keratoconus, a rare and sight-threatening corneal disease. Epioxa is the first FDA-approved topical drug therapy for keratoconus that does not require removal of the corneal epithelium, aiming to improve patient comfort and reduce recovery time. Glaukos intends to make Epioxa commercially available in the first quarter of 2026 and plans to invest in patient awareness, access programs, and educational initiatives to address the underdiagnosis and undertreatment of keratoconus. No other organizations were mentioned as recipients of this regulatory approval.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251020818094) on October 20, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.